Florida-California Cancer Research, Education and Engagement (CaRE) Health Equity Center: Structure, Innovations, and Initial Outcomes

• Published in: Cancer Control
• Main Authors: R. Renee Reams, Folakemi T. Odedina, John D. Carpten, Kinfe Redda, Mariana C. Stern, Janice L. Krieger, Jose Aparicio, Brooke Hensel, Nissa Askins, Andre Abreu, Angela Adams, Edward Agyare, Jamel Ali, John M. Allen, Richard Aló, Lourdes Baezconde-Garbanati, Jason Brant, Clyde P. Brown, Sarah G. Buxbaum, Pinchas Cohen, Wendy Cozen, Miriam O. Ezenwa, Sara Falzarano, Roger B. Fillingim, Hernan Flores-Rozas, Kristianna M. Fredenburg, Thomas George, Bo Han, Yong Huang, Chanita Hughes Halbert, Gebre-Egziabher Kiros, Nazarius S. Lamango, Ji-Hyun Lee, Debra E. Lyon, Duane A. Mitchell, Bereket Mochona, Jorge J. Nieva, Ite A. Offringa, Paul Okunieff, Alexander Parker, Suhn K. Rhie, Joyce M. Richey, Sherise C. Rogers, Bodour Salhia, Thomas D. Schmittgen, Richard Segal, Veronica W. Setiawan, Ukamaka Smith, Li-Ming Su, Sandra Suther, Jose Trevino, Enrique I. Velazquez-Villarreal, Fern J. Webb, Anna H. Wu, Yingwei Yao, Diana J. Wilkie
• Format: Article
• Language: English
• Published: SAGE Publishing 2023-08-01
• Online Access: https://doi.org/10.1177/10732748231197878

Introduction The Florida-California Cancer Research, Education, and Engagement (CaRE 2 ) Health Equity Center is a triad partnership committed to increasing institutional capacity for cancer disparity research, the diversity of the cancer workforce, and community empowerment. This article provides an overview of the structure, process innovations, and initial outcomes from the first 4 years of the CaRE 2 triad partnership. Methods CaRE 2 serves diverse populations in Florida and California using a “molecule to the community and back” model. We prioritize research on the complex intersection of biological, environmental, and social determinants health, working together with scientific and health disparities communities, sharing expertise across institutions, bidirectional training, and community outreach. Partnership progress and outcomes were assessed using mixed methods and four Program Steering Committee meetings. Results Research capacity was increased through development of a Living Repository of 81 cancer model systems from minority patients for novel cancer drug development. CaRE 2 funded 15 scientific projects resulting in 38 publications. Workforce diversity entailed supporting 94 cancer trainees (92 URM) and 34 ESIs (32 URM) who coauthored 313 CaRE 2 -related publications and received 48 grants. Community empowerment was promoted via outreaching to more than 3000 individuals, training 145 community cancer advocates (including 28 Community Scientist Advocates), and publishing 10 community reports. CaRE 2 members and trainees together have published 639 articles, received 61 grants, and 57 awards. Conclusion The CaRE 2 partnership has achieved its initial aims. Infrastructure for translational cancer research was expanded at one partner institution, and cancer disparities research was expanded at the two cancer centers.